Rituximab maintenance significantly reduces early follicular
lymphoma progressions in patients treated with frontline R-CHOP

J 2020

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP

PROCHÁZKA, Vít; David BELADA; Andrea JANÍKOVÁ; Kateřina BENEŠOVÁ; Heidi MOCIKOVÁ et al.

Základní údaje

Originální název

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP

Autoři

Vydání

eJHaem, Hoboken, Wiley, 2020, 2688-6146

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00118146

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/jha2.60

UT WoS

001229275600043

Klíčová slova anglicky

Rituximab; early follicular lymphoma

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 10. 2024 15:31, Mgr. Natálie Hílek

Anotace

V originále

Twenty percent of patients with high-tumor-burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to reduce relapse rate in responding FL, but its role on preventing POD was not defined. We analyzed 1360 HTB-FL patients from the Czech Lymphoma Study Group registry treated with frontline rituximab-containing regimen. Of those, 950 cases received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and achieved complete or partial remission: 712 patients received rituximab maintenance (MAINT) and 238 were a historical observational cohort (OBS). We have proposed a modified POD24 (mPOD24) endpoint for the chemosensitive patients calculated from the end-of-induction (EOI). Survival rates since EOI were as follows: 5-year overall survival (OS) 86.2% versus 94.5% in the OBS and MAINT groups, respectively (P < .001) and 5-year progression-free survival 58.5% (OBS) and 75.4% (MAINT) (P < .001). The Cox proportional hazards model showed a decrease in mPOD24 incidence in the MAINT group with the overall hazard rate reduced by 56% (hazard ratio = 0.44; P < .001). The cumulative incidence of mPOD24 was reduced from 24.1% in OBS to 10.1% in MAINT (P < .001). Comparison of non-mPOD24 cases showed OS similar to that in the general population. Rituximab maintenance given after R-CHOP resulted in a 2.4-fold reduction in mPOD24 incidence. Once the non-POD24 status is achieved, FL does not shorten the patients life expectancy.

Citovat

PROCHÁZKA, Vít; David BELADA; Andrea JANÍKOVÁ; Kateřina BENEŠOVÁ; Heidi MOCIKOVÁ; Juraj ĎURAŠ; Jan PIRNOS; Kateřina KOPEČKOVÁ; Vít CAMPR; Tomáš FÜRST; Robert PYTLÍK; Alice SÝKOROVÁ; Jozef MICHALKA; Jitka DLOUHÁ; Tomáš PAPAJÍK a Marek TRNĚNÝ. Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. eJHaem. Hoboken: Wiley, 2020, roč. 2020, č. 1, s. 170-180. ISSN 2688-6146. Dostupné z: https://doi.org/10.1002/jha2.60.

@article{1740583,
   author = {Procházka, Vít and Belada, David and Janíková, Andrea and Benešová, Kateřina and Mociková, Heidi and Ďuraš, Juraj and Pirnos, Jan and Kopečková, Kateřina and Campr, Vít and Fürst, Tomáš and Pytlík, Robert and Sýkorová, Alice and Michalka, Jozef and Dlouhá, Jitka and Papajík, Tomáš and Trněný, Marek},
   article_location = {Hoboken},
   article_number = {1},
   doi = {https://doi.org/10.1002/jha2.60},
   keywords = {Rituximab; early follicular lymphoma},
   language = {eng},
   issn = {2688-6146},
   journal = {eJHaem},
   title = {Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP},
   url = {https://onlinelibrary.wiley.com/doi/full/10.1002/jha2.60},
   volume = {2020},
   year = {2020}
}

TY  - JOUR
ID  - 1740583
AU  - Procházka, Vít - Belada, David - Janíková, Andrea - Benešová, Kateřina - Mociková, Heidi - Ďuraš, Juraj - Pirnos, Jan - Kopečková, Kateřina - Campr, Vít - Fürst, Tomáš - Pytlík, Robert - Sýkorová, Alice - Michalka, Jozef - Dlouhá, Jitka - Papajík, Tomáš - Trněný, Marek
PY  - 2020
TI  - Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP
JF  - eJHaem
VL  - 2020
IS  - 1
SP  - 170-180
EP  - 170-180
PB  - Wiley
SN  - 26886146
KW  - Rituximab
KW  - early follicular lymphoma
UR  - https://onlinelibrary.wiley.com/doi/full/10.1002/jha2.60
L2  - https://onlinelibrary.wiley.com/doi/full/10.1002/jha2.60
N2  - Twenty percent of patients with high-tumor-burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to reduce relapse rate in responding FL, but its role on preventing POD was not defined. We analyzed 1360 HTB-FL patients from the Czech Lymphoma Study Group registry treated with frontline rituximab-containing regimen. Of those, 950 cases received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and achieved complete or partial remission: 712 patients received rituximab maintenance (MAINT) and 238 were a historical observational cohort (OBS). We have proposed a modified POD24 (mPOD24) endpoint for the chemosensitive patients calculated from the end-of-induction (EOI). Survival rates since EOI were as follows: 5-year overall survival (OS) 86.2% versus 94.5% in the OBS and MAINT groups, respectively (P < .001) and 5-year progression-free survival 58.5% (OBS) and 75.4% (MAINT) (P < .001). The Cox proportional hazards model showed a decrease in mPOD24 incidence in the MAINT group with the overall hazard rate reduced by 56% (hazard ratio = 0.44; P < .001). The cumulative incidence of mPOD24 was reduced from 24.1% in OBS to 10.1% in MAINT (P < .001). Comparison of non-mPOD24 cases showed OS similar to that in the general population. Rituximab maintenance given after R-CHOP resulted in a 2.4-fold reduction in mPOD24 incidence. Once the non-POD24 status is achieved, FL does not shorten the patients life expectancy.
ER  -

PROCHÁZKA, Vít; David BELADA; Andrea JANÍKOVÁ; Kateřina BENEŠOVÁ; Heidi MOCIKOVÁ; Juraj ĎURAŠ; Jan PIRNOS; Kateřina KOPEČKOVÁ; Vít CAMPR; Tomáš FÜRST; Robert PYTLÍK; Alice SÝKOROVÁ; Jozef MICHALKA; Jitka DLOUHÁ; Tomáš PAPAJÍK a Marek TRNĚNÝ. Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. \textit{eJHaem}. Hoboken: Wiley, 2020, roč.~2020, č.~1, s.~170-180. ISSN~2688-6146. Dostupné z: https://doi.org/10.1002/jha2.60.

Přehled o publikaci